Continued complete remission after a PML/RAR-alpha+ autograft in acute promyelocytic leukaemia.
Ruiz-Argüelles
G J
GJ
Garcés-Eisele
J
J
Ruiz-Argüelles
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006085:Graft Survival; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009363:Neoplasm Proteins / Q000097:blood*; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000637:transplantation*; D015514:Oncogene Proteins, Fusion / Q000097:blood*; D012074:Remission Induction; D014182:Transplantation, Autologous; D014212:Tretinoin / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D003561:Cytarabine; D014212:Tretinoin; D004317:Doxorubicin